Coccidioidomycosis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:


==Treatment==
==Treatment==
The drug therapy is guided by the severity of symptoms and the immune status of the patient. Since most patients are asymptomatic or mildly affected, no treatment or a single drug Azole therapy (fluconazole or itraconazole) may be sufficient in these cases.However patients with HIV, immune-compromised, those on steroids or pregnant females need much more aggressive approach.More recently resistant cases are being treated with voriconazole or posaconazole.<ref name="Chen-2011">{{Cite journal | last1 = Chen | first1 = S. | last2 = Erhart | first2 = LM. | last3 = Anderson | first3 = S. | last4 = Komatsu | first4 = K. | last5 = Park | first5 = B. | last6 = Chiller | first6 = T. | last7 = Sunenshine | first7 = R. | title = Coccidioidomycosis: knowledge, attitudes, and practices among healthcare providers--Arizona, 2007. | journal = Med Mycol | volume = 49 | issue = 6 | pages = 649-56 | month = Aug | year = 2011 | doi = 10.3109/13693786.2010.547995 | PMID = 21247229 }}</ref>. More severe cases may require intravenous Amphotericin B, with or without simultaneous oral azole therapy. Pregnant females are treated by Intravenous amphotericin B only.
The drug therapy is guided by the severity of symptoms and the immune status of the patient. Since most patients are asymptomatic or mildly affected, no treatment or a single drug azole therapy (fluconazole or itraconazole) may be sufficient in these cases. More recently resistant cases are being treated with voriconazole or posaconazole.<ref name="Chen-2011">{{Cite journal | last1 = Chen | first1 = S. | last2 = Erhart | first2 = LM. | last3 = Anderson | first3 = S. | last4 = Komatsu | first4 = K. | last5 = Park | first5 = B.| last6 = Chiller | first6 = T. | last7 = Sunenshine | first7 = R. | title = Coccidioidomycosis: knowledge, attitudes, and practices among healthcare providers--Arizona, 2007. | journal = Med Mycol | volume = 49 | issue = 6 | pages = 649-56 | month = Aug | year = 2011 | doi = 10.3109/13693786.2010.547995 | PMID = 21247229}}</ref>. However patients with HIV, immune-compromised, those on steroids or pregnant females need much more aggressive approach. More severe cases may require intravenous amphotericin B, with or without simultaneous oral azole therapy. Meningitis or vasculitis often need initial in-patient treatment with oral azoles plus intravenous amphotericin B with or without intrathecal amphotericin B. Untreated cases may sometimes be fatal.
 
Severe cases like meningitis or vasculitis often need initial in-patient treatment with oral azoles plus intravenous amphotericin B with or without intrathecal amphotericin B. Untreated cases may sometimes be fatal.
 


Pregnant females are treated by Intravenous amphotericin B only.
==References==
==References==



Revision as of 21:59, 19 November 2013

Coccidioidomycosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Coccidioides immitis
Coccidioides posadasii

Differentiating Coccidioidomycosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Coccidioidomycosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Coccidioidomycosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Coccidioidomycosis medical therapy

CDC on Coccidioidomycosis medical therapy

Coccidioidomycosis medical therapy in the news

Blogs on Coccidioidomycosis medical therapy

Directions to Hospitals Treating Coccidioidomycosis

Risk calculators and risk factors for Coccidioidomycosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: ; Vidit Bhargava, M.B.B.S [2]

Treatment

The drug therapy is guided by the severity of symptoms and the immune status of the patient. Since most patients are asymptomatic or mildly affected, no treatment or a single drug azole therapy (fluconazole or itraconazole) may be sufficient in these cases. More recently resistant cases are being treated with voriconazole or posaconazole.[1]. However patients with HIV, immune-compromised, those on steroids or pregnant females need much more aggressive approach. More severe cases may require intravenous amphotericin B, with or without simultaneous oral azole therapy. Meningitis or vasculitis often need initial in-patient treatment with oral azoles plus intravenous amphotericin B with or without intrathecal amphotericin B. Untreated cases may sometimes be fatal.

Pregnant females are treated by Intravenous amphotericin B only.

References

  1. Chen, S.; Erhart, LM.; Anderson, S.; Komatsu, K.; Park, B.; Chiller, T.; Sunenshine, R. (2011). "Coccidioidomycosis: knowledge, attitudes, and practices among healthcare providers--Arizona, 2007". Med Mycol. 49 (6): 649–56. doi:10.3109/13693786.2010.547995. PMID 21247229. Unknown parameter |month= ignored (help)

Template:WH Template:WS